Research Study

A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Myopathy Followed by an Open-Label Treatment Extension
Principal Investigator 
Anna Lehman

Overview

Body Locations and Systems 
Disorders and Conditions 
ClinicalTrials.gov# 
NCT03323749
Status 
Recruiting
Study Start/End 
May 11, 2018 to Dec 31, 2020
Locations 
Diamond Health Care Centre
Name/Title 
Anita Thomas, Research Coordinator
Phone 
604-875-3806
Email Address 
athomas2@cw.bc.ca
Purpose of Study 

The purpose of this study is to evaluate the safety and efficacy of daily subcutaneous injections of elamipretide in subjects with primary mitochondrial myopathy.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.